CRISPR-based therapeutics hold potential to combat AMR
Clustered regularly interspaced short palindromic repeats (CRISPR)-based therapeutics are rapidly gaining traction for the management of infectious diseases. Programs targeting pathogens such as the human immunodeficiency virus (HIV), herpes simplex virus (HSV), and drug-resistant Escherichia coli (E. coli) are advancing in the clinic, signaling a transformative shift in the infectious disease space.
CRISPR-based therapeutics show potential to combat antimicrobial resistance (AMR) and deliver functional cures for chronic viral infections, says pharma analytics company GlobalData.
GlobalData’s latest report, “CRISPR Gene Editing in Infectious Diseases: Market Overview”, reveals that programmable gene editing technologies are now being investigated in clinical trials to address long-standing unmet needs in both viral and bacterial infections, with companies such as Excision BioTherapeutics, BDGene Therapeutics, Locus Biosciences and SNIPR Biome leading the charge.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze